These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26209418)

  • 1. We need to move more: Neurobiological hypotheses of physical exercise as a treatment for Parkinson's disease.
    Monteiro-Junior RS; Cevada T; Oliveira BR; Lattari E; Portugal EM; Carvalho A; Deslandes AC
    Med Hypotheses; 2015 Nov; 85(5):537-41. PubMed ID: 26209418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing neurogenesis for the possible treatment of Parkinson's disease.
    Lamm O; Ganz J; Melamed E; Offen D
    J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise-induced neuroplasticity in human Parkinson's disease: What is the evidence telling us?
    Hirsch MA; Iyer SS; Sanjak M
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S78-81. PubMed ID: 26439945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits and mechanisms of exercise training for Parkinson's disease.
    Feng YS; Yang SD; Tan ZX; Wang MM; Xing Y; Dong F; Zhang F
    Life Sci; 2020 Mar; 245():117345. PubMed ID: 31981631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson disease and exercise.
    Earhart GM; Falvo MJ
    Compr Physiol; 2013 Apr; 3(2):833-48. PubMed ID: 23720332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
    Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
    Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation.
    Sharma N; Nehru B
    Neurochem Int; 2015 Aug; 87():92-105. PubMed ID: 26055970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise and Parkinson's disease.
    Xu X; Fu Z; Le W
    Int Rev Neurobiol; 2019; 147():45-74. PubMed ID: 31607362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical Exercise-Induced Activation of NRF2 and BDNF as a Promising Strategy for Ferroptosis Regulation in Parkinson's Disease.
    Thirupathi A; Marqueze LF; Outeiro TF; Radak Z; Pinho RA
    Neurochem Res; 2024 Jul; 49(7):1643-1654. PubMed ID: 38782838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease.
    Chao J; Leung Y; Wang M; Chang RC
    Nutr Rev; 2012 Jul; 70(7):373-86. PubMed ID: 22747840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
    Tripathy D; Chakraborty J; Mohanakumar KP
    Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies in Parkinson's disease: what we have learned from animal models.
    Valadas JS; Vos M; Verstreken P
    Ann N Y Acad Sci; 2015 Mar; 1338():16-37. PubMed ID: 25515068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
    Datta I; Bhonde R
    Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.